Sequential paclitaxel reduces recurrence and mortality in women with early breast cancer

References 

1. Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352:930–942, 1998
2. Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1–15, 1992
3. Fisher B, Brown AM, Dimitrov NV, et al.  Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J. Clin. Oncol. 1990;8:1483–1496
   • MEDLINE
4. Fisher B, Anderson S, Wickerham DL. Increased intensification and total dose of cyclophosphamide in a doxorubicin–cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J. Clin. Oncol. 1997;15:1858–1869
   • MEDLINE
5. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol. 2003;21(6):963–964
   • MEDLINE
   • CrossRef
6. Bishop JF, Dewar J, Toner GC, et al.  Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J. Clin. Oncol. 1999;17:2355–2364
   • MEDLINE
7. Nabholtz JM, Falkson G, Campos D, Szanto J, Martin M, Chan S. A phase III trial comparing doxorubicin and docetaxel to doxorubicin and cyclophosphamide as first line chemotherapy for metastatic breast cancer. Proc. ASCO. 1999;18:127a
8. Adjuvant Therapy for Breast Cancer. (17(4)), 1–35. 2001. Kensington, MD, National Institutes of Health. NIH Consensus Statement
9. Mamounas EP, Bryant J, Lembersky BC, Fisher B, Atkins JN, Fehrenbacher L, et al. Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. Proc. Am. Soc. Clin. Oncol. 2003;22:4
10. Buzdar AU, Singletary SE, Valero V, et al.  Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res. 2002;8:1073–1079
    • MEDLINE
11. Nabholtz J-M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Vogel C, Weaver C, Walley B, Martin M, Chap L, Tomiak E, Juhos E, Guevin R, Howell A, Hainsworth J, Fornander T, Blitz S, Gazel S, Loret C, Riva A., and Breast Cancer International Research Group. Phase III Trial Comparing TAC (Docetaxel, Doxorubicin, Cyclophosphamide) with FAC (5-Fluorouracil, Doxorubicin, Cyclophosphamide) in the Adjuvant Treatment of Node Positive Breast Cancer Patients: Interim Analysis of the BCIRG 001 Study. Proc Am Soc Clin Oncol 2002; 21
12. Green MC, Buzdar AU, Smith T, et al.  Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3-week (Q 3 wk) P therapy (tx) followed by FAC – final results of a prospective phase III randomized trial. Proc. Am. Soc. Clin. Oncol. 2002;21:35a
13. Citron ML, Berry DA, Cirrincione C, et al.  Randomized trial of dose–dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 2003;21:1431–1439
    • MEDLINE
    • CrossRef